Anavex (AVXL) Life Sciences reported a peer-reviewed publication in the journal iScience, ascertaining the precise autophagy mechanism of sigmar-1 receptor through blarcamesine activation, titled “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.” This new publication confirms with additional biochemical data in more detail the autophagy restoration mechanism of S1R activation with blarcamesine. The specific S1R-localized motif responsible for physiologically relevant interactions with autophagy proteins-promoting autophagosome biogenesis, autophagic cargo reception, and lysosome fusion-was confirmed and modulated by blarcamesine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex announces new publication on blarcamesine in Alzheimer’s
- Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry
- Anavex Life Sciences Reports Q3 2025 Financial Results
- Anavex reports Q3 EPS (16c) vs (14c) last year
- AVXL Earnings Report this Week: Is It a Buy, Ahead of Earnings?